Page last updated: 2024-12-05
benzopurpurine 4b
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
benzopurpurine 4B: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 13816 |
| CHEMBL ID | 1471289 |
| SCHEMBL ID | 1897261 |
| MeSH ID | M0049992 |
Synonyms (83)
| Synonym |
|---|
| cerven prima 2 |
| 1-naphthalenesulfonic acid, 3,3'-((3,3'-dimethyl(1,1'-biphenyl)-4,4'-diyl)bis(2,1-diazenediyl))bis(4-amino-, sodium salt (1:2) |
| unii-g519jhx5mj |
| g519jhx5mj , |
| ditolylbis(azonaphthionic acid) |
| ai3-62957 |
| disodium o-tolidinediazobis(1-naphthylamine-4-sulfonate) |
| einecs 213-594-3 |
| diaphtamine purpurine |
| nsc 5015 |
| 1-naphthalenesulfonic acid, 3,3'-((3,3'-dimethyl(1,1'-diphenyl)-4,4'-diyl)bis(azo))bis(4-amino-, disodium salt |
| 1-naphthalenesulfonic acid, 3,3'-((3,3'-dimethyl(1,1'-biphenyl)-4,4'-diyl)bis(azo))bis(4-amino-, disodium salt |
| paper red 4b |
| tetrodirect red 4b |
| hsdb 4226 |
| ccris 690 |
| cerven prima 2 [czech] |
| amanil purpurine |
| benzanil purpurine 4b |
| azocard red 4b |
| tertrodirect red 4b |
| diphenyl red 4bs |
| diazine red 4b |
| benzopurpurine 4bkx |
| paper red 4bs |
| phenamine purpurine 4b |
| chrome leather red 4b |
| diphenyl red 4b |
| amanil purpurine 4b |
| c.i. direct red 2, disodium salt |
| benzopurpurine 4bx |
| atul direct red 4b |
| c.i. direct red 2 disodium salt |
| brasilamina red 4b |
| diacotton benzopurpurine 4b |
| direct red dcb |
| direct purpurine m4b |
| diaphtamine purpurine 4b |
| calcomine red 4bx |
| direct red 2 |
| erie benzo 4bp |
| ditolybis(azonaphthionic acid) |
| direct purpurine 4b |
| mitsui benzopurpurine 4bx |
| nsc-5015 |
| diazamine purpurine 4b |
| diamine purpurine 4b |
| direct red 4b |
| benzopurpurin 4b |
| kayaku benzopurpurine 4b |
| bencidal purple 4b |
| hispamin red 4b |
| diazol purpurine 4b |
| benzopurpurin b |
| c.i. 23500 |
| c.i. direct red 2 |
| 992-59-6 |
| benzopurpurine 4b |
| NCGC00091339-01 |
| disodium 3,3'-(3,3'-dimethyl(1,1'-biphenyl)-4,4'-diyl)bis(azo)bis(4-aminonaphthalene-1-sulphonate) |
| direct red 2 (c.i. 23500) |
| B0781 |
| AKOS000282537 |
| dtxsid3025203 , |
| cas-992-59-6 |
| NCGC00260057-01 |
| dtxcid105203 |
| tox21_202508 |
| SCHEMBL1897261 |
| 3,3'-((3,3'-dimethyl(1,1'-biphenyl)-4,4'-diyl)bis(2,1-diazenediyl))bis(4-amino-1-naphthalenesulfonic acid) sodium salt (1:2) |
| ci direct red 2 |
| sultan red 4b |
| benzopurpurine 4b [mi] |
| c.i. direct red 2 [hsdb] |
| CHEMBL1471289 |
| benzopurpurin4b |
| mfcd00012410 |
| disodium 4-amino-3-((e)-{4'-[(e)-(1-amino-4-sulfonato-2-naphthyl)diazenyl]-3,3'-dimethyl[1,1'-biphenyl]-4-yl}diazenyl)-1-naphthalenesulfonate |
| sodium 3,3'-(1e,1'e)-(3,3'-dimethylbiphenyl-4,4'-diyl)bis(diazene-2,1-diyl)bis(4-aminonaphthalene-1-sulfonate) |
| Q818516 |
| brasilamina red 4b; c.i. 23500; calcomine red 4bx; chrome leather red 4b |
| D88688 |
| disodium;4-amino-3-[[4-[4-[(1-amino-4-sulfonatonaphthalen-2-yl)diazenyl]-3-methylphenyl]-2-methylphenyl]diazenyl]naphthalene-1-sulfonate |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Feces were assayed for 14C content and for unchanged dosed dyes or amines by HPLC." | ( Metabolism and distribution of two 14C-benzidine-congener-based dyes in rats as determined by GC, HPLC, and radioassays. Billedeau, SM; Bowman, MC; Nony, CR; Oller, WL; Rowland, KL, ) | 0.13 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (52)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 25.1189 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 8.9221 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 8.9221 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 12.5893 | 0.1259 | 19.1169 | 125.8920 | AID2549 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 7.9433 | 0.0020 | 14.6779 | 39.8107 | AID1476; AID1478 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 71.3274 | 0.0025 | 41.7960 | 15,848.9004 | AID1347395; AID1347398 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 0.3981 | 0.0126 | 10.6917 | 88.5700 | AID887 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 30.7937 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 27.6773 | 0.1737 | 34.3047 | 61.8120 | AID1346859 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 27.6773 | 0.1737 | 34.3047 | 61.8120 | AID1346859 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 0.1077 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 7.2136 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID588516; AID743035; AID743042; AID743053; AID743054; AID743063 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 6.3096 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 7.6379 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 21.2514 | 0.0002 | 14.3764 | 60.0339 | AID588532; AID588533; AID720692 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 30.7937 | 0.0030 | 41.6115 | 22,387.1992 | AID1159555 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 7.4193 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 19.4295 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 18.8068 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID1259383; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 31.6228 | 0.0126 | 8.1569 | 44.6684 | AID2101 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 44.6684 | 0.0010 | 19.4141 | 70.9645 | AID588537 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 48.8047 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | Potency | 14.1254 | 1.0000 | 12.2326 | 31.6228 | AID1452 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 10.0000 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 47.3935 | 0.0100 | 39.5371 | 1,122.0200 | AID1469; AID1479 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 26.9283 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 15.8489 | 0.0398 | 16.7842 | 39.8107 | AID995 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 29.6071 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID743202; AID743219 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 12.5893 | 0.0200 | 10.7869 | 31.6228 | AID912 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 3.1623 | 0.3162 | 12.7657 | 31.6228 | AID881 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 7.7350 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 35.9595 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID651743 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 7.7350 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 3.1623 | 0.0063 | 8.2350 | 39.8107 | AID881 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (144)
Molecular Functions (41)
Ceullar Components (25)
Research
Studies (4)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.28
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.28) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||